Cargando…

Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study

BACKGROUND: Varenicline is an effective pharmacotherapy to aid smoking cessation. However, its use is limited by continuing concerns about possible associated risks of serious adverse cardiovascular and neuropsychiatric events. The aim of this study was to investigate whether use of varenicline is a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotz, Daniel, Viechtbauer, Wolfgang, Simpson, Colin, van Schayck, Onno C P, West, Robert, Sheikh, Aziz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593936/ https://www.ncbi.nlm.nih.gov/pubmed/26355008 http://dx.doi.org/10.1016/S2213-2600(15)00320-3

Ejemplares similares

Cardiovascular and neuropsychiatric safety of varenicline and bupropion compared with nicotine replacement therapy for smoking cessation: study protocol of a retrospective cohort study using the QResearch general practice database
por: Kotz, Daniel, et al.
Publicado: (2014)

Development and validation of a model to predict the 10-year risk of general practitioner-recorded COPD
por: Kotz, Daniel, et al.
Publicado: (2014)

The efficacy and safety of a nicotine conjugate vaccine (NicVAX(®)) or placebo co-administered with varenicline (Champix(®)) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial
por: Hoogsteder, Philippe HJ, et al.
Publicado: (2012)

Validity of urges to smoke measures in predicting smoking relapse during treatment in primary care
por: Kotz, Daniel, et al.
Publicado: (2021)

Prospective cohort study of the effectiveness of varenicline versus nicotine replacement therapy for smoking cessation in the “real world”
por: Kotz, Daniel, et al.
Publicado: (2014)

Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis
por: Thomas, Kyla H, et al.
Publicado: (2015)

Neuropsychiatric safety of varenicline in the general and COPD population with and without psychiatric disorders: a retrospective cohort study in a real-world setting
por: Wang, Yuanyuan, et al.
Publicado: (2021)

A comparison of the characteristics of iOS and Android users of a smoking cessation app
por: Ubhi, Harveen Kaur, et al.
Publicado: (2017)

Evaluation of the cardiovascular effects of varenicline in rats
por: Selçuk, Engin Burak, et al.
Publicado: (2015)

Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study
por: Svanström, Henrik, et al.
Publicado: (2012)

Poor reporting may infer poor science: lessons learned from asthma trials
por: Been, Jasper V, et al.
Publicado: (2013)

Characterising smoking cessation smartphone applications in terms of behaviour change techniques, engagement and ease-of-use features
por: Ubhi, Harveen Kaur, et al.
Publicado: (2015)

Risk of neuropsychiatric adverse events associated with varenicline treatment for smoking cessation among Dutch population: A sequence symmetry analysis
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Comparative analysis of smoking cessation smartphone applications available in 2012 versus 2014
por: Ubhi, Harveen Kaur, et al.
Publicado: (2016)

Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors
por: Beard, Emma, et al.
Publicado: (2021)

Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial
por: Kotz, Daniel, et al.
Publicado: (2007)

Risk of neuropsychiatric and cardiovascular adverse events following treatment with varenicline and nicotine replacement therapy in the UK Clinical Practice Research Datalink: a case–cross‐over study
por: Thomas, Kyla H., et al.
Publicado: (2020)

Could APO-varenicline and cytisine be solutions for the shortage of varenicline in Brazil?
por: Corrêa, Paulo César Rodrigues Pinto, et al.
Publicado: (2023)

Development and validation of a multivariable mortality risk prediction model for COPD in primary care
por: Shah, Syed A., et al.
Publicado: (2022)

Publisher Correction: Development and validation of a multivariable mortality risk prediction model for COPD in primary care
por: Shah, Syed A., et al.
Publicado: (2022)

External validation of a COPD prediction model using population-based primary care data: a nested case-control study
por: Nwaru, Bright I, et al.
Publicado: (2017)

Varenicline in the treatment of tobacco dependence
por: Fagerström, Karl, et al.
Publicado: (2008)

Smoking cessation therapy with varenicline
por: Mohanasundaram, Uma M, et al.
Publicado: (2008)

Varenicline in smokers with diabetes: A pooled analysis of 15 randomized, placebo‐controlled studies of varenicline
por: Tonstad, Serena, et al.
Publicado: (2016)

Assessment of the Risk of Suicide-Related Events Induced by Concomitant Use of Antidepressants in Cases of Smoking Cessation Treatment with Varenicline and Assessment of Latent Risk by the Use of Varenicline
por: Akimoto, Hayato, et al.
Publicado: (2016)

Motivation to stop smoking in the German population between 2016 - 2021 and associated factors: results from a repeated cross-sectional representative population survey (German Study on Tobacco Use, DEBRA study)
por: Borchardt, Benjamin, et al.
Publicado: (2023)

Chronic obstructive pulmonary disease: a disease of old age?
por: Boudewijns, Esther A, et al.
Publicado: (2018)

Effectiveness of varenicline and counselling for smoking cessation in an observational cohort study in China
por: Jiang, Bin, et al.
Publicado: (2016)

The Food and Drug Administration and varenicline: should risk communication be improved?
por: Davies, Neil M., et al.
Publicado: (2016)

Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis
por: Prochaska, Judith J, et al.
Publicado: (2012)

Smoking cessation in Asians: focus on varenicline
por: Xiao, Dan, et al.
Publicado: (2015)

The psychiatric effects of varenicline on patients with depression
por: Yeung, EYH, et al.
Publicado: (2015)

Impact of smoke-free legislation on perinatal and infant mortality: a national quasi-experimental study
por: Been, Jasper V, et al.
Publicado: (2015)

Experiences of tobacco smoking and quitting in smokers with and without chronic obstructive pulmonary disease-a qualitative analysis
por: van Eerd, Eva A. M., et al.
Publicado: (2015)

The association between self-reported varenicline adherence and varenicline blood levels in a sample of cancer patients receiving treatment for tobacco dependence
por: Crawford, Grace, et al.
Publicado: (2018)

Retreatment With Varenicline for Smoking Cessation in Smokers Who Have Previously Taken Varenicline: A Randomized, Placebo-Controlled Trial
por: Gonzales, D, et al.
Publicado: (2014)

Varenicline and Risk of Self-Harm: A Nested Case-Control Study
por: Tadrous, Mina, et al.
Publicado: (2016)

Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
por: Sterling, Lee H., et al.
Publicado: (2016)

Smoking cessation: an economic analysis and review of varenicline
por: Faulkner, Michele A
Publicado: (2009)

Identification, Isolation and Characterization of an Unknown Impurity of Varenicline
por: Satheesh, Balasubramanian, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_g9ao56oapvl79c2gudsiq219hj